Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT3A | Q9Y6K1 | 4/20 | 0.49 |
| ▸ | EHMT2 | Q96KQ7 | 4/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.49 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.49 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 7/20 | 0.49 |
| ▸ | CCR3 | P51677 | 3/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4118769 | 0.95 | ACHE (0.52) | DNMT3AEHMT2KDM1ARCOR1MCHR1 | |
| SCHEMBL5194216 | 0.93 | DNMT3A (0.53) | DNMT3AEHMT2KDM1ARCOR1MCHR1 | |
| SCHEMBL4838974 | 0.93 | DNMT3A (0.54) | DNMT3AEHMT2KDM1ARCOR1MCHR1 | |
| SCHEMBL4837275 | 0.92 | ACHE (0.54) | DNMT3AEHMT2KDM1ARCOR1MCHR1 | |
| Hydrochloric Acid SCHEMBL4833934 | 0.92 | DNMT3A (0.52) | DNMT3AEHMT2KDM1ARCOR1MCHR1 | |
| SCHEMBL4843894 | 0.92 | MCHR1 (0.55) | DNMT3AEHMT2KDM1ARCOR1MCHR1 | |
| SCHEMBL5193821 | 0.92 | DNMT3A (0.51) | DNMT3AEHMT2KDM1ARCOR1MCHR1 | |
| SCHEMBL4837358 | 0.92 | DNMT3A (0.51) | DNMT3AEHMT2KDM1ARCOR1MCHR1 | |
| SCHEMBL4843357 | 0.91 | MCHR1 (0.52) | DNMT3AMCHR1CCR3KCNH2 | |
| SCHEMBL4833949 | 0.91 | ACHE (0.56) | DNMT3AEHMT2KDM1ARCOR1MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7423030-B2 | 1-amino-phthalazine derivatives, the preparation and the therapeutic use thereof | SANOFI-AVENTIS (FR) | 2008-09-09 | — | — | US | claimed |
| EP-1737840-B1 | 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2007-09-12 | — | — | EP | claimed |
| US-20070099895-A1 | 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-05-03 | — | — | US | claimed |
| US-7423030-B2 | 1-amino-phthalazine derivatives, the preparation and the therapeutic use thereof | SANOFI-AVENTIS (FR) | 2008-09-09 | — | — | US | disclosed |
| EP-1737840-B1 | 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2007-09-12 | — | — | EP | disclosed |
| US-20070099895-A1 | 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-05-03 | — | — | US | disclosed |
| EP-1737840-A1 | 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005103033-A1 | 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099895-A1 | 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF | CYP11B2, CYP11B1, GOT2 | DNMT3A 4219/4885EHMT2 1339/4885KDM1A 2445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.